-20℃ 3 years powder
-80℃ 2 years in solvent
SNS-314 Mesylate is an effective and specific Aurora A/B/C inhibitor (IC50: 9/31/3 nM). It is less inhibition of Trk A/B, Fms, Flt4, c-Raf, Axl, and DDR2.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | Inquiry | 52.00 | |
5 mg | In stock | 94.00 | |
10 mg | In stock | 169.00 | |
25 mg | In stock | 300.00 | |
50 mg | In stock | 380.00 | |
100 mg | In stock | 690.00 | |
1 mL * 10 mM (in DMSO) | Inquiry | 115.00 |
Description | SNS-314 Mesylate is an effective and specific Aurora A/B/C inhibitor (IC50: 9/31/3 nM). It is less inhibition of Trk A/B, Fms, Flt4, c-Raf, Axl, and DDR2. |
Targets&IC50 | Aurora A :ic50 9nM, Aurora B :ic50 31nM, Aurora C :ic50 3nM, |
Kinase Assay | Aurora-A Kinase Assay: Humanized mouse Aurora A (amino acids 107-403) is expressed in E. coli as described previously. For IC50 assays, compounds are titrated three-fold in DMSO and diluted 12.5-fold into assay buffer (10 mM Tris HCl pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.01% Tween-20, and 0.1% BSA). Compounds are then diluted 4-fold into assay buffer containing Aurora A and FAM-PKAtide at final concentrations of 2 nM and 50 nM, respectively. The kinase reaction is initiated by adding ATP in assay buffer at a final concentration of 10 mM and incubated at 21 °C for 25 minutes. As a positive control, DMSO is added instead of compound and as a negative control assay buffer is added instead of Aurora A. Both control reactions are conducted in triplicate. To detect phosphorylated PKAtide, the kinase reaction is combined with Progressive Binding Solution (1:400 Progressive Binding Reagent, 1 × Buffer A, Molecular Devices) in a 1:3 ratio. The mixture is incubated for 30 minutes at 21 °C and the plate is scanned on an Analyst AD with excitation at 485 nm and emission at 530 nm. The percent relative enzymatic activity is calculated by normalizing the mP value for each well to the average positive control. Relative enzymatic activity values are plotted as a function of the logarithm of compound concentration and IC50 values are generated in GraphPad Prism software using a sigmoidal dose-response curve-fit. IC50's are calculated as the concentration of compound at which enzymatic activity i |
Cell Research |
Viability is measured using the CellTiter-Blue cell viability assay. Cells are treated as described above, although with a 5-day incubation period. Cytotoxicity is determined by measuring intracellular ATP using the CellTiter-Glo Luminescence Cell Viability Assay. Cells are seeded in white 96-well tissue culture plates at a density of 1.5-2 × 103 cells/well, and a serial dilution of SNS-314 is dosed in combination with fixed concentrations of either docetaxel or vincristine for a total of 72 hours. Viability is determined as the ratio between the ATP in treated cells versus control cells. Apoptosis is measured using the caspase-Glo 3/7 system. Cells are plated in white 96-well plates as described above and treated first with SNS-314 for 24 hours, washed with 200 μL of 1× PBS, and fresh medium is added with the second agent for 24 hours.(Only for Reference)
Cell lines: HCT116 SCR and HCT116 p53 RNAi cells
|
Animal Research |
Animal Model: HCT116 cells are injected s.c. into the right flank of nu/nu mice.
|
Synonyms | SNS-314 |
Purity | 99.92% |
Molecular Weight | 527.04 |
Formula | C18H15ClN6OS2·CH4O3S |
CAS No. | 1146618-41-8 |
-20℃ 3 years powder
-80℃ 2 years in solvent
DMSO: 52.7 mg/mL (100 mM)
( < 1 mg/ml refers to the product slightly soluble or insoluble )
15% Captisol: 30 mg/mL
Safe and effective drug dosing is necessary, regardless of its purpose of administration. Learn More
bottom
Answers to questions you may have can be found in the Inhibitor Handling Instructions. Topics include how to prepare stock solutions, how to store Products, and issues that need special attention for cell-based assays and animal experiments.